Is Boundless Bio, Inc. Common Stock (BOLD) overvalued? · P/E 0.1, $24.6M cap
Boundless Bio, Inc. Common Stock (BOLD) is a biotechnology company listed on US.
This page asks whether Boundless Bio, Inc. Common Stock (BOLD) looks expensive on cached numbers — not a short thesis.
No cached income statement for BOLD, so there is no earnings base to call rich or cheap.
BOLD currently screens at market cap $24.6M and trailing P/E 0.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BOLD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BOLD stock page for the full model, not this heading.
Not investment advice.